Haiyong Peng

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Venues

Nature biomedical engineering

Oncogene

PLoS pathogens

Antibody therapeutics

Scripps Florida

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Scripps Florida Sep 01 2012

United States

Staff Scientist :: Immunology and Microbiology

Publications

Yiming Yin, Yan Guo, Yuxuan Jiang, Brian Quinlan, Haiyong Peng, Gogce Crynen, Wenhui He, Lizhou Zhang, Tianling Ou, Charles C Bailey, Michael Farzan
In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. Nature biomedical engineering (2024)
Haiyong Peng, Thomas Nerreter, Katrin Mestermann, Jakob Wachter, Jing Chang, Michael Hudecek, Christoph Rader
Correction: ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene (2024)
Yiming Yin, Yan Guo, Yuxuan Jiang, Brian Quinlan, Haiyong Peng, Gogce Crynen, Wenhui He, Lizhou Zhang, Tianling Ou, Charles C Bailey, Michael Farzan
In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. Nature biomedical engineering (2024)
Yiming Yin, Yan Guo, Yuxuan Jiang, Brian Quinlan, Haiyong Peng, Gogce Crynen, Wenhui He, Lizhou Zhang, Tianling Ou, Charles C Bailey, Michael Farzan
In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. Nature biomedical engineering 8 (4) (2024)
Yiming Yin, Yan Guo, Yuxuan Jiang, Brian Quinlan, Haiyong Peng, Gogce Crynen, Wenhui He, Lizhou Zhang, Tianling Ou, Charles C Bailey, Michael Farzan
In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. Nature biomedical engineering (2024)
Yiming Yin, Yan Guo, Yuxuan Jiang, Brian Quinlan, Haiyong Peng, Gogce Crynen, Wenhui He, Lizhou Zhang, Tianling Ou, Charles C Bailey, Michael Farzan
In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. Nature biomedical engineering (2024)
Yiming Yin, Yan Guo, Yuxuan Jiang, Brian Quinlan, Haiyong Peng, Gogce Crynen, Wenhui He, Lizhou Zhang, Tianling Ou, Charles C Bailey, Michael Farzan
In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. Nature biomedical engineering 8 (4) (2024)
Jing Chang, Christoph Rader, Haiyong Peng
A mammalian cell display platform based on scFab transposition. Antibody therapeutics 6 (3) (2023)
Matthew G Cyr, Maissa Mhibik, Junpeng Qi, Haiyong Peng, Jing Chang, Erika M Gaglione, David Eik, John Herrick, Thomas Venables, Scott J Novick, Valentine V Courouble, Patrick R Griffin, Adrian Wiestner, Christoph Rader
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia. Journal for immunotherapy of cancer 10 (11) (2022)
Haiyong Peng, Thomas Nerreter, Katrin Mestermann, Jakob Wachter, Jing Chang, Michael Hudecek, Christoph Rader
ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene 41 (34) (2022)
Huihui Mu, Brian D Quinlan, Haiyong Peng, Guan Qun Liu, Yan Guo, Shoujiao Peng, Lizhou Zhang, Meredith E Davis-Gardner, Matthew R Gardner, Gogce Crynen, Lindsey B DeVaux, Zhi Xiang Voo, Charles C Bailey, Michael D Alpert, Christoph Rader, Michaela U Gack, Hyeryun Choe, Michael Farzan
Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2. PLoS pathogens 17 (4) (2021)
Lizhou Zhang, Cody B Jackson, Huihui Mou, Amrita Ojha, Haiyong Peng, Brian D Quinlan, Erumbi S Rangarajan, Andi Pan, Abigail Vanderheiden, Mehul S Suthar, Wenhui Li, Tina Izard, Christoph Rader, Michael Farzan, Hyeryun Choe
SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nature communications 11 (1) (2020)

Haiyong Peng.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Haiyong Peng